November 1, 2019
A key health ministry panel on October 31 gave the go-ahead for the approval of Novartis Pharma’s asthma drug Xolair (omalizumab) for the treatment of seasonal allergic rhinitis, or pollen allergy. If approved, it will be the first antibody drug...read more